Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; H.R. 6, 21st Century Cures Act, provisions related to DME infusion drugs. Medicare reimbursement methodology for DME infused drugs, generally.
Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
2016 · first_quarter · 1T
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; H.R. 6, 21st Century Cures Act, provisions related to DME infusion drugs. Medicare reimbursement methodology for DME infused drugs, generally.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; H.R. 6, 21st Century Cures Act, provisions related to DME infusion drugs. Medicare reimbursement methodology for DME infused drugs, generally.
Preservation of Access for Seniors in Medicare Advantage Act of 2015
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; H.R. 6, 21st Century Cures Act, provisions related to DME infusion drugs. Medicare reimbursement methodology for DME infused drugs, generally.
Preservation of Access for Seniors in Medicare Advantage Act of 2015
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; H.R. 6, 21st Century Cures Act, provisions related to DME infusion drugs. Medicare reimbursement methodology for DME infused drugs, generally.
21st Century Cures Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; H.R. 6, 21st Century Cures Act, provisions related to DME infusion drugs. Medicare reimbursement methodology for DME infused drugs, generally.
21st Century Cures Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; H.R. 6, 21st Century Cures Act, provisions related to DME infusion drugs. Medicare reimbursement methodology for DME infused drugs, generally.
National Clinical Care Commission Act
Client: NOVO NORDISK, INC. · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Issues related to the prevention and treatment of diabetes, including the National Diabetes Clinical Care Commission Act (H.R. 1192/S. 586); Medicare Part D reimbursement; the Treat and Reduce Obesity Act.
National Clinical Care Commission Act
Client: NOVO NORDISK, INC. · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
H.R. 1192/S. 586, The National Diabetes Clinical Care Commission Act.
National Clinical Care Commission Act
Client: NOVO NORDISK, INC. · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
H.R. 1192/S. 586, The National Diabetes Clinical Care Commission Act.
National Clinical Care Commission Act
Client: NOVO NORDISK, INC. · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
H.R. 1192/S. 586, The National Diabetes Clinical Care Commission Act.
National Clinical Care Commission Act
Client: NOVO NORDISK, INC. · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Issues related to the prevention and treatment of diabetes, including the National Diabetes Clinical Care Commission Act (H.R. 1192/S. 586); Medicare Part D reimbursement; the Treat and Reduce Obesity Act.
Patients' Access to Treatments Act of 2015
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
FY16 FDA Agriculture-Rural Development appropriations bill, provisions related to plasma protein therapies; H.R. 1600, Patients Access to Treatment Act.
Treat and Reduce Obesity Act of 2015
Client: NOVO NORDISK, INC. · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Medicare reimbursement for Part D drugs; H.R. 2404 and S. 1509, Treat and Reduce Obesity Act.
Treat and Reduce Obesity Act of 2015
Client: NOVO NORDISK, INC. · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Medicare reimbursement for Part D drugs; H.R. 2404 and S. 1509, Treat and Reduce Obesity Act. S.1131, Medicare Diabetes Prevention Act of 2015.
Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; Medicare reimbursement methodology for DME infused drugs, generally.
Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; H.R. 6, 21st Century Cures Act, provisions related to DME infusion drugs. Medicare reimbursement methodology for DME infused drugs, generally.
Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; H.R. 6, 21st Century Cures Act, provisions related to DME infusion drugs. Medicare reimbursement methodology for DME infused drugs, generally.
Preservation of Access for Seniors in Medicare Advantage Act of 2015
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; H.R. 6, 21st Century Cures Act, provisions related to DME infusion drugs. Medicare reimbursement methodology for DME infused drugs, generally.
Preservation of Access for Seniors in Medicare Advantage Act of 2015
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; H.R. 6, 21st Century Cures Act, provisions related to DME infusion drugs. Medicare reimbursement methodology for DME infused drugs, generally.
Preservation of Access for Seniors in Medicare Advantage Act of 2015
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; Medicare reimbursement methodology for DME infused drugs, generally.
21st Century Cures Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; H.R. 6, 21st Century Cures Act, provisions related to DME infusion drugs. Medicare reimbursement methodology for DME infused drugs, generally.
21st Century Cures Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; H.R. 6, 21st Century Cures Act, provisions related to DME infusion drugs. Medicare reimbursement methodology for DME infused drugs, generally.
Medicare Diabetes Prevention Act of 2015
Client: NOVO NORDISK, INC. · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Medicare reimbursement for Part D drugs; H.R. 2404 and S. 1509, Treat and Reduce Obesity Act. S.1131, Medicare Diabetes Prevention Act of 2015.
Treat and Reduce Obesity Act of 2015
Client: NOVO NORDISK, INC. · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Medicare reimbursement for Part D drugs; H.R. 2404 and S. 1509, Treat and Reduce Obesity Act. S.1131, Medicare Diabetes Prevention Act of 2015.
Treat and Reduce Obesity Act of 2015
Client: NOVO NORDISK, INC. · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Medicare reimbursement for Part D drugs; H.R. 2404 and S. 1509, Treat and Reduce Obesity Act.
National Diabetes Clinical Care Commission Act
Client: NOVO NORDISK, INC. · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Issues related to the prevention and treatment of diabetes, including the National Diabetes Clinical Care Commission Act (H.R. 1192/S. 586); Medicare Part D reimbursement; the Treat and Reduce Obesity Act.
National Diabetes Clinical Care Commission Act
Client: NOVO NORDISK, INC. · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
H.R. 1192/S. 586, The National Diabetes Clinical Care Commission Act.
National Diabetes Clinical Care Commission Act
Client: NOVO NORDISK, INC. · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
Issues related to the prevention and treatment of diabetes, including the National Diabetes Clinical Care Commission Act (H.R. 1192/S. 586); Medicare Part D reimbursement; the Treat and Reduce Obesity Act.
National Diabetes Clinical Care Commission Act
Client: NOVO NORDISK, INC. · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
H.R. 1192/S. 586, The National Diabetes Clinical Care Commission Act.
National Diabetes Clinical Care Commission Act
Client: NOVO NORDISK, INC. · Firm: BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
H.R. 1192/S. 586, The National Diabetes Clinical Care Commission Act.
2016 · first_quarter · Q1
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; H.R. 6, 21st Century Cures Act, provisions related to DME infusion drugs. Medicare reimbursement methodology for DME infused drugs, generally.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
2015 · fourth_quarter · Q4
H.R. 1192/S. 586, The National Diabetes Clinical Care Commission Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
2015 · fourth_quarter · Q4
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; H.R. 6, 21st Century Cures Act, provisions related to DME infusion drugs. Medicare reimbursement methodology for DME infused drugs, generally.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
2015 · third_quarter · Q3
H.R. 1192/S. 586, The National Diabetes Clinical Care Commission Act.
Medicare reimbursement for Part D drugs; H.R. 2404 and S. 1509, Treat and Reduce Obesity Act. S.1131, Medicare Diabetes Prevention Act of 2015.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
2015 · third_quarter · Q3
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; H.R. 6, 21st Century Cures Act, provisions related to DME infusion drugs. Medicare reimbursement methodology for DME infused drugs, generally.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
2015 · second_quarter · Q2
Medicare reimbursement for Part D drugs; H.R. 2404 and S. 1509, Treat and Reduce Obesity Act.
H.R. 1192/S. 586, The National Diabetes Clinical Care Commission Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
2015 · second_quarter · Q2
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; Medicare reimbursement methodology for DME infused drugs, generally.
FY16 FDA Agriculture-Rural Development appropriations bill, provisions related to plasma protein therapies; H.R. 1600, Patients Access to Treatment Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK, INC. via BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ
2015 · second_quarter · RR
Issues related to the prevention and treatment of diabetes, including the National Diabetes Clinical Care Commission Act (H.R. 1192/S. 586); Medicare Part D reimbursement; the Treat and Reduce Obesity Act.
Issues related to the prevention and treatment of diabetes, including the National Diabetes Clinical Care Commission Act (H.R. 1192/S. 586); Medicare Part D reimbursement; the Treat and Reduce Obesity Act.